Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109442 · ClinicalTrials.gov registry record · Phase 1
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
A Phase 1 study, sponsored by Affimed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT05109442 is a Phase 1 study that was terminated before completion, run by Affimed. The registered enrollment target is 112 participants.
The verdict
NCT05109442, a Phase 1 study, was terminated before completion, sponsored by Affimed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Interventions
- DRUG AFM24
- DRUG Atezolizumab 840 MG in 14 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05109442
The ClinicalTrials.gov registry entry for NCT05109442 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affimed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AFM24 is the first listed.
NCT05109442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05109442 about?
NCT05109442 is a clinical study titled "Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers". AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therap...
What is the current status of trial NCT05109442?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2021-11-19. Estimated completion is 2025-06-11.
What interventions are being tested in trial NCT05109442?
The interventions under investigation include: AFM24 (DRUG), Atezolizumab 840 MG in 14 ML Injection (DRUG).
Who is sponsoring clinical trial NCT05109442?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.